Sindrome de Atra
Alberto Vizueth Martínez1, Erika Belem Moedano Álvarez2, Daniel Ramírez Morelos3, Juliette Areli López Villeda3, Diana Ramírez Trejo3.
1. Maestro en Administración de los Servicios de Salud/Jefe de Investigación del Hospital del Niño DIF Hidalgo, México
2. Licenciada en Farmacia/Jefe del Servicio de Farmacia del Hospital del Niño DIF Pachuca Hidalgo, México.
3. Pasantes de la Licenciatura en Farmacia Universidad Autónoma del Estado de Hidalgo, México.
Resumen |Abstract | Texto completo | Descargar cuerpo en pdf |
The leukemia promyelocytic acute (APL) is the subtype of leukemia myeloid acute of better prognosis in children. Its incidence is less than 10%. From the point of view cytogenetic is observed a translocation t (15; 17). The addition of the acid transretinoico has achieved high rates of complete remission because of the rapid disappearance of the coagulopathy and,
consequently, decrease in the rate of relapses, compared with monotherapy treatment. In general it is a well-tolerated drug but can have adverse reactions; the most serious is transretinoico acid (ATRA), potentially fatal syndrome. The manifestations are: fever, weight gain, pulmonary infiltrates, syndrome of shortness of breath, hypotension, pleural effusion or pericardial, hepatic and renal insufficiency. The treatment is with suspension of the acid transretinoico, measures of support and high doses of steroids. It presents a case clinical of the Hospital del Niño DIF with APL and syndrome of ATRA.
Key words: Trans retinoic acid, ATRA syndrome, acute promyelocitic leukemia |
